Galimedix, Inc. | WebDisclosure

PRESS RELEASE

published on 05/06/2025 at 14:00, 1 year 3 months ago

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
Galimedix Therapeutics completes single ascending dose of Phase 1 study with oral small molecule GAL-101 targeting amyloid beta aggregation modulator, supporting oral administration route. Next study arms and indications revealed

Galimedix Therapeutics GAL-101 Oral Administration Phase 1 Study Amyloid Beta
BRIEF

published on 04/01/2025 at 09:05, 1 year 4 months ago

Galimedix Reports Promising Data for Alzheimer's Treatment

Alzheimer's Disease GAL-201 Galimedix Therapeutics Neuroinflammation Amyloid-β Aggregation
BRIEF

published on 04/01/2025 at 09:05, 1 year 4 months ago

Galimedix publie des données prometteuses pour le traitement de la maladie d'Alzheimer

GAL-201 Maladie D'Alzheimer Galimedix Therapeutics Neuroinflammation Agrégation De L'amyloïde-β
PRESS RELEASE

published on 04/01/2025 at 09:00, 1 year 4 months ago

Galimedix Therapeutics presents further scientific data showing disease-modifying potential of oral GAL-201 in Alzheimer’s disease as well as beneficial effects on synaptic function and neuroimmunomod
Galimedix Therapeutics presents new preclinical data on GAL-201 at AD/PD 2025, showing promise in Alzheimer’s disease treatment by targeting misfolded Aβ monomers and reducing Aβ plaques with anti-inflammatory effects

Alzheimer's Disease Preclinical Data GAL-201 Galimedix Therapeutics Neuroinflammation
BRIEF

published on 03/24/2025 at 15:12, 1 year 4 months ago

Galimedix Therapeutics présente un traitement préclinique prometteur contre la maladie d'Alzheimer

Galimedix Therapeutics Neuroprotection Données Précliniques Traitement De La Maladie D'Alzheimer Bêta-amyloïde
BRIEF

published on 03/24/2025 at 15:12, 1 year 4 months ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta
PRESS RELEASE

published on 03/24/2025 at 15:07, 1 year 4 months ago

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference

Alzheimer's Disease Galimedix Therapeutics Pre-clinical Data AD/PD 2025 Conference Aβ Aggregation Modulator
BRIEF

published on 12/23/2024 at 17:35, 1 year 7 months ago

Galimedix débute un essai de phase 2 avec les gouttes ophtalmiques GAL-101 pour la DMLA sèche

Étude De Phase 2 Neuroprotection GAL-101 DMLA Sèche Atrophie Géographique
BRIEF

published on 12/23/2024 at 17:35, 1 year 7 months ago

Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Phase 2 Study Neuroprotection GAL-101 Dry AMD Geographic Atrophy
PRESS RELEASE

published on 12/23/2024 at 17:30, 1 year 7 months ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy

Published on 08/19/2026 at 22:00, 2 hours 16 minutes ago

Jaguar Health Reports Second Quarter 2026 Financials
Published on 08/19/2026 at 20:35, 3 hours 41 minutes ago

Revive Therapeutics Announces Proposed Shares for Debt Settlement
Published on 08/19/2026 at 18:50, 5 hours 26 minutes ago

AmeriTrust Auto Advances End-to-End Lease Remarketing Strategy
Published on 08/19/2026 at 16:00, 8 hours 16 minutes ago

Telefónica Chile and Amdocs Establish Strategic Multi-Year Agreement to Accelerate Modernization and Business Agility in Chile
Published on 08/19/2026 at 15:55, 8 hours 21 minutes ago

Drill Permit Received for Storm Exploration's Gold Standard Project

View all ACCESSWIRE

Published on 08/19/2026 at 18:45, 5 hours 31 minutes ago

NNS acquires shares in OCI
Published on 08/19/2026 at 18:00, 6 hours 16 minutes ago

Dividend Declaration
Published on 08/19/2026 at 17:37, 6 hours 39 minutes ago

Monthly Performance Factsheet
Published on 08/19/2026 at 16:51, 7 hours 25 minutes ago

AUTODOC and Apollo Funds successfully conclude transformative partnership
Published on 08/19/2026 at 16:15, 8 hours 1 minute ago

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc

View all EQS

Published on 08/18/2026 at 18:00, 1 day 6 hours ago

KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 1 day 6 hours ago

Mise à disposition du rapport financier annuel 2025-26
Published on 08/18/2026 at 11:15, 1 day 13 hours ago

GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026
Published on 08/18/2026 at 11:15, 1 day 13 hours ago

GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 19:45, 2 days 4 hours ago

Aéroports de Paris S.A - July 2026 traffic figures

View all LES ECHOS COMFI WIRE

News